Literature DB >> 32590008

COVID-19 and type 1 diabetes: Challenges and actions.

Emma L Klatman1, Stéphane Besançon2, Silver Bahendeka3, Mary Mayige4, Graham D Ogle5.   

Abstract

Entities:  

Keywords:  COVID 19; Diabetes; Insulin; Supply chain; Type 1 diabetes

Mesh:

Year:  2020        PMID: 32590008      PMCID: PMC7311352          DOI: 10.1016/j.diabres.2020.108275

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


× No keyword cloud information.
In response to the Coronavirus Disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2), as of May 2020, almost all nations have enforced strict measures to contain the spread of the virus. These include countrywide lockdowns, whereby internal travel has been restricted and borders have been closed. These measures have severe negative impacts on national economies. COVID-19 is challenging all diabetes services, but the situation is particularly perilous for people with type 1 diabetes (T1D) in Low-and-middle income countries (LMICs). Even in non-pandemic times, access to insulin, blood glucose monitoring, and expert clinical care is often challenging to maintain due to lack of affordable and available provision [1]. Continual access to these components is essential to prevent serious acute complications and deaths. The authors of this commentary are involved in the care of T1D in LMICs and see services in such settings suffering in three major ways from the impacts of COVID-19. These include the immediate impact of lockdowns and restrictions on international transport; the need for accurate information for patients, carers and health professionals; and the medium-to long-term impacts on health budgets. Using country examples known to us, these challenges and their evolving responses are described below.

Lockdowns and restrictions on international transport

Lockdowns are placing increased hardships on people with T1D with regards to accessing their daily medical supplies, attending clinic appointments, and accessing emergency care for acute complications such as hypoglycaemia and diabetic ketoacidosis (DKA). This is due to stay-at-home measures, less available transportation, business closures, and lost family income. In response, diabetes centres in various countries are addressing these challenges with courage and innovation. Volunteers with T1D along with health professionals and their own families are delivering supplies over long distances on motorbikes and by taxi, after gaining police permits, in Sri Lanka, Rwanda, Uganda and India. The lockdowns have also increased the price of food and decreased access to it. Such food insecurity is particularly dangerous for people with T1D. Diabetes associations in Rwanda, Uganda, Democratic Republic of Congo, Malawi, Ghana, and Mauritania are providing food parcels and other support to families with a child or youth with T1D. These distribution efforts are being supported by Life for a Child (LFAC), Partners in Health, Marjorie’s Fund, Sonia Nabeta Foundation and others. Curtailment of international flights has resulted in difficulties with deliveries of supplies, particularly insulin given its cold-chain requirements. A large shipment of LFAC-donated insulin was stuck in-transit at an airport in Germany for several few weeks until a route to Ethiopia was found, which was at much greater expense than usual costs. For some other LFAC insulin shipments, ocean freight using refrigerated containers is currently being considered as no air-freight options are available. The Insulin for Life network is sending out emergency parcels to various countries. Further compounding delivery difficulties, government shutdowns are delaying customs approvals for shipments of insulin and blood glucose meters and strips. Finally, many centres caring for young people with T1D in LMICs rely on income from private patients or local donors to provide care to lower-income families, and these sources of funds have been sharply reduced. LFAC has provided staff support and funds for personal protective equipment (PPE) for Maldives and Bolivia.

Need for accurate information

The pandemic has led to much global anxiety, which is heightened in anyone with a pre-existing condition such as T1D. There is also much misinformation. In addition to imposed internal travel restrictions, various countries have reported a reduction in routine clinic visits due to fear from people with T1D. It is essential that accurate information is disseminated that covers general advice (e.g., the importance of social distancing, and hand-washing), sick-day management to prevent DKA, and reassurance about risk. It is also critical that clinics provide 24-hour call services for advice. Diabetes education webinars are being delivered by Fundación Diabetes Juvenil in Ecuador. In Mali, more than 1000 people with diabetes are receiving prevention messages from Santé Diabète via SMS. In India, Samatvam Endocrinology Diabetes Centre is delivering telemedicine using WhatsApp. Rwanda also has a WhatsApp group run by T1D health professionals. There is also a need for information for health professionals looking after patients with diabetes and COVID-19, covering the importance of good blood glucose control in hospital, and management of DKA outside the usual intensive care setting. A concern reported to authors of this article include delayed presentation in DKA of new-onset or existing T1D cases [2], a potentially fatal situation. In Tanzania, the Ministry of Health issued a statement which emphasises that people living with chronic diseases must continue to access routine medical care and treatment for acute symptoms. The French NGO Santé Diabète has developed a COVID-19 Response Strategy [3] with the Mali and Burkina Faso Ministry of Health and the Kenya Diabetes Study Group has distributed a statement on recommendations for health care providers and patients living with diabetes. The International Society for Pediatrics and Adolescent Diabetes [4], International Diabetes Federation, the American Diabetes Association [5], and the JDRF and Beyond Type 1 Alliance [6] have developed useful resources. An article was published by the Lancet Diabetes & Endocrinology concerning practical recommendations for people with T1D [7]. We encourage groups to produce and widely disseminate their local advice.

Impact on health budgets

Damage to national economies is profound in all countries, but the impact will be particularly severe on LMICs due to reduced tourism, trade, investment, and capacity for economic stimulus. Decreased health budgets could threaten country procurement of essential medicines (such as insulin) and other supplies critical for T1D care, which would both imperil care of indigent individuals with T1D and impede country progress towards universal health coverage of diabetes care [8]. In-country diabetes associations and other stakeholders should compile information on annual demand, previous orders, current reserves, and identify supply gaps, possible alternate suppliers, and local challenges such as customs approvals and logistics, and then maintain advocacy at sufficiently high levels until the supplies and other budget lines are secured. Fig. 1 summarises the impacts, resultant problems, and some possible solutions.
Fig. 1

International actions and recommendations

Many national and international organisations, agencies and foundations are working to address needs for people with T1D and other forms of diabetes. In April 2020, LFAC and JDRF initiated the COVID-19 Diabetes Supplies Coalition (CDSC) [9]. To date, 22 organisations and foundations are participating, including the International Diabetes Federation, the Helmsley Charitable Trust, NCD Alliance, the International Insulin Foundation, Defeat NCD, NGO Santé Diabète and others. The aims are to identify shortages of insulin, other diabetes supplies, and clinical care, that result from disruptions caused by COVID-19, and then to mobilise support and share best practices so that these needs can be met as well as possible. The CDSC has begun distributing monthly digests summarizing country developments and homegrown and international solutions. Various pharma companies are also participating in the information exchange. On 18th May 2020, the COVID-19 response draft resolution was proposed to the 73rd World Health Assembly. It emphasises the impacts that the pandemic will have on people with noncommunicable diseases [10]. Looking ahead, on the international level, concerted efforts focused on the welfare of young people with T1D are required to ensure stability of care during and beyond the COVID-19 pandemic. The current crisis also highlights the need for governments to invest in patient registries and strengthen telemedicine capacity.
  3 in total

Review 1.  Levels of type 1 diabetes care in children and adolescents for countries at varying resource levels.

Authors:  Graham D Ogle; Julia E von Oettingen; Angela C Middlehurst; Ragnar Hanas; Trevor J Orchard
Journal:  Pediatr Diabetes       Date:  2018-12-10       Impact factor: 4.866

2.  Documenting and visualising progress towards Universal Health Coverage of insulin and blood glucose test strips for people with diabetes.

Authors:  Emma Louise Klatman; Martin McKee; Graham David Ogle
Journal:  Diabetes Res Clin Pract       Date:  2019-09-20       Impact factor: 5.602

Review 3.  Practical recommendations for the management of diabetes in patients with COVID-19.

Authors:  Stefan R Bornstein; Francesco Rubino; Kamlesh Khunti; Geltrude Mingrone; David Hopkins; Andreas L Birkenfeld; Bernhard Boehm; Stephanie Amiel; Richard Ig Holt; Jay S Skyler; J Hans DeVries; Eric Renard; Robert H Eckel; Paul Zimmet; Kurt George Alberti; Josep Vidal; Bruno Geloneze; Juliana C Chan; Linong Ji; Barbara Ludwig
Journal:  Lancet Diabetes Endocrinol       Date:  2020-04-23       Impact factor: 32.069

  3 in total
  4 in total

1.  COVID-19 pandemic and transmission factors: An empirical investigation of different countries.

Authors:  Pawan Kumar Singh; Ravi Kiran; Rajiv Kumar Bhatt; Mosab I Tabash; Alok Kumar Pandey; Anushka Chouhan
Journal:  J Public Aff       Date:  2021-02-20

2.  Does COVID-19 predispose patients to type 1 diabetes mellitus?

Authors:  Aysun Ata; Arzu Jalilova; Tarık Kırkgöz; Hafize Işıklar; Günay Demir; Yasemin Atik Altınok; Behzat Özkan; Ayşin Zeytinlioğlu; Şükran Darcan; Samim Özen; Damla Gökşen
Journal:  Clin Pediatr Endocrinol       Date:  2021-11-01

3.  Perceived impact of the COVID-19 pandemic on young adults with type 1 diabetes in Rwanda.

Authors:  Jean Claude Habineza; Steven James; Laurien Sibomana; Emma Klatman; Etienne Uwingabire; Jayanthi Maniam; Graham David Ogle
Journal:  Pan Afr Med J       Date:  2021-12-21

Review 4.  COVID-19 and diabetes mellitus: from pathophysiology to clinical management.

Authors:  Soo Lim; Jae Hyun Bae; Hyuk-Sang Kwon; Michael A Nauck
Journal:  Nat Rev Endocrinol       Date:  2020-11-13       Impact factor: 47.564

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.